報價延遲最少15分鐘:2024/10/31 23:26 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.54/0.53
|
|
企業價值
32.75M
|
| 資產負債 |
|
每股賬面淨值
1.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
19.05M
|
|
每股收益
1.73
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/10/31 23:26 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting the front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema. |